Thrombin is a positive mediator of thrombus formation through the proteolytic activation of PARs, fibrinogen, fXI and other substrates, and a negative regulator through activation of protein C, a natural anticoagulant with anti-inflammatory/cytoprotective properties. Protease engineering studies have established that two active site substitutions, W215A/E217A (fII WE ), result in dramatically reduced catalytic efficiency with procoagulant substrates while largely preserving TM-dependent protein C activation. To explore the hypothesis that a prothrombin variant favoring antithrombotic pathways would be compatible with development, but limit inflammatory processes in vivo, we generated mice carrying the fII WE mutations within the endogenous prothrombin gene. Unlike fII-null embryos, fII WE/WE mice uniformly developed to term. Nevertheless, these mice ultimately succumbed to spontaneous bleeding events shortly after birth. Heterozygous fII WT/WE mice were viable and fertile despite a shift toward an antithrombotic phenotype exemplified by prolonged tail-bleeding times and times-to-occlusion
Introduction
The conversion of prothrombin to the active serine protease thrombin is a central event in hemostasis/thrombosis as well as the regulation of embryonic development, vascular barrier function, tissue repair, tumor progression, and inflammatory processes. 1 In the context of hemostasis, thrombin directly promotes the formation and stabilization of thrombi through the proteolytic activation of protease activated receptors (e.g., PAR-1 and -4), the proteolytic conversion of fibrinogen to fibrin, and the activation of fXI, fVIII, fV, fXIII and other substrates.
However, in direct opposition to these procoagulant pathways, when bound to the endothelial cell receptor thrombomodulin (TM), the proteolytic specificity of thrombin is dramatically altered such that the ability to activate procoagulant factors is suppressed in favor of enhanced activation of the natural anticoagulant, protein C. 2 Thrombin-mediated cleavage of PARs, protein C, complement proteins, cytokines, and growth factors is proposed to be important in the control of cellular proliferation, migration, apoptosis, adhesion, process outgrowth, and other fundamental elements of cell biology. [3] [4] [5] [6] [7] [8] [9] The extraordinary capacity of thrombin to engage a wide array of biologically important substrates and dramatically switch proteolytic specificity in vivo has made thrombin a centerpiece of detailed structural and biological analysis.
Structure-function studies have identified two active site variants, W215A and E217A, which strongly diminished procoagulant activity, but largely retained TM-dependent anticoagulant function as defined by the capacity to activate protein C. 10, 11 Analyses of the compound mutant, thrombin W215A/E217A (thrombin WE ) established that this variant exhibited even greater selectivity for protein C over procoagulant substrates. The catalytic efficiency of human thrombin WE with fibrinogen and PAR-1 expressed in terms of k cat /K m , was found to be diminished approximately 19,000-fold and 1200-fold, respectively, with a far more modest reduction in activity toward protein C (i.e., ~7-fold change in k cat /K m ). 12 Thus, the net effect of these active site alterations was a molecule with little procoagulant function but preserved anticoagulant potential. Another striking feature of the thrombin WE variant was a pronounced resistance to inactivation by the physiological inhibitor antithrombin III (ATIII); the k on for ATIII is reduced 3000-fold relative to wild-type thrombin. 12 Studies of human thrombin WE infused into experimental animals have established that this engineered protease can act as a potent and long lasting anticoagulant molecule in vivo. 13, 14 A few notable differences exist between human and murine thrombin. The murine enzyme is constitutively stabilized in the high activity state similar to the Na + -bound form of human thrombin. 15 Nevertheless, imposition of the W215A/E217A mutations in murine thrombin was shown to result in a shift in catalytic activity that is qualitatively comparable to that observed with human enzyme, albeit quantitatively less profound. Specifically, the k cat /K m of murine thrombin WE with murine fibrinogen and PAR-1 is diminished approximately 1200-fold and 60-fold, respectively, while the k cat /K m for protein C is diminished a more modest 6-fold 15 . These data would suggest that, in balance, murine thrombin WE , like the human variant, would tend to significantly favor anticoagulant over procoagulant substrates.
Multiple lines of evidence suggest a role for thrombin-mediated proteolysis, and procoagulant function in particular, in the pathogenesis of arthritis and other inflammatory diseases. [16] [17] [18] The specific thrombin inhibitor hirudin was shown to be effective in limiting both collagen-induced arthritis (CIA) and antigen-induced arthritis (AIA) in mice. 19, 20 Complementary studies of fibrinogen gene-targeted mice established that fibrin is at least one thrombin substrate that drives CIA disease progression and severity. 21 Additional studies have shown that mice deficient in PAR-1 were partially resistant to K/BxN serum transfer arthritis. 22 These observations, and provocative recent findings establishing that the thrombin product APC has potent anti-inflammatory/barrier-stabilization/cytoprotective activities in vitro and in vivo, [23] [24] [25] [26] [27] lend support to the concept that a pro/thrombin variant with limited activity for fibrinogen and
PARs, but retained activity for protein C, would attenuate the progression of inflammatory joint disease. To explore the general hypothesis that prothrombin active site mutations favoring an anticoagulant phenotype would be compatible with developmental success, but limit inflammatory processes in vivo, gene-targeted mice were generated and characterized carrying the fII WE mutations within the endogenous prothrombin gene.
Materials and Methods

Generation of fII WE gene-targeted mice
The fII WE targeting vector was generated by PCR-based mutagenesis in which 4 nucleotide substitutions were introduced into exon 14 that converted amino acids tryptophan 215 and glutamic acid 217 (chymotrypsin numbering system) into alanine residues. The complete targeting vector included a mutagenized 710 bp short arm, an approximately 4.7 kb long arm, a 3.6 kb HPRT minigene, and a 2 kb HSV-tk minigene. E14Tg2a ES cell clones that incorporated the targeting vector by homologous recombination were identified by PCR analysis using primers complementary to HPRT (5'-AAATGCTCCAGACTGCCTTG-3') and the prothrombin gene (5'-GTACAAGAGAAGGCTGTGACTTGGCCAGAG-3') that generated an 838 bp product. The presence of the mutation was confirmed by PCR using primers upstream (5'- 
Analysis of fII WE expression and hematological profiles
Comparative analyses of hepatic mRNA were done by RT-PCR using total adult liver RNA. First stand cDNA synthesis was performed with 1 μg of total RNA using a Thermoscript Comparative thrombin generation assays (TGA) were done using a Technothrombin TGA kit (Technoclone) as described by the manufacturer for mouse citrate plasma. Thrombin generation was initiated in vitro by addition of calcium and lipids containing recombinant tissue factor and thrombin activity was measured by cleavage of a fluorogenic thrombin substrate using a FLx800 fluorescence plate reader (Biotek). Tail bleeding times were established in ketamine/xylazineanesthetized mice by excising 3 mm of tail tip and submerging it in Tris-buffered saline (pH 7.5) containing 2 mM CaCl 2 at 37°C.
RT-PCR kit (Invitrogen
Comparative real-time analyses of thrombus formation by intravital microscopy
Intravital microscopic analysis of thrombus formation within injured mesenteric arterioles was done in tribromoethanol-anesthesitized (0.15 mL of 2.5% per 10 g body weight) 3-to 4-week-old animals (14 to 18g) infused with fluorescent platelets (2.5 x 10 9 platelets/kg) through the retro-orbital plexus, as described previously. 29 Vessel centerline velocities were measured using an optical Doppler velocity meter (Microcirculation Research Institute) and shear rate was calculated as previously described. 29 An endothelial injury was induced by a 5 minute topical application of Whatman paper (Whatman) saturated with 10% FeCl 3 . Vessels were monitored by fluorescence microscopy for 40 minutes after injury, or until occlusion. Key experimental endpoints were the time required for formation of a thrombus larger than 30 μm and the occlusion time (i.e., the time required for blood to stop flowing for 30 seconds). Chemicals). APC levels were measured immunologically using a murine specific APC antibody, as previously described. 30 , Mice were infused with a large bolus (150 μg) of human APC three minutes prior blood collection to displace any EPCR-bound murine APC into the circulation.
Survival and plasma APC levels following endotoxin challenge
Collagen-induced arthritis
Cohorts of 6-to 8-week-old male mice backcrossed to the CIA-susceptible DBA/1J genetic background were twice immunized with 100 µg of bovine collagen type II (CII) (Elastin Products Co., Inc.) in complete Freund's adjuvant (CFA) on days 1 and 21. Mice were evaluated for arthritis using an arthritic index macroscopic scoring system ranging from 0 to 4 (0 = no arthritis, 1 = swelling and/or redness of paw or one digit, 2 = two arthritic joints, 3 = three arthritic joints, and 4 = severe arthritis of the entire paw and digit). 21 CII-specific cell proliferation assays with cultured T cells from popliteal lymph node cells and CII-specific plasma antibody titers were determined as previously described. 31 In experiments utilizing recombinant thrombin WE , inbred DBA/1 mice (Jackson Laboratories) were immunized as described and given daily retrorbital injections of the purified recombinant protein beginning at day 21 of the CIA protocol at a dose of 0.1 mg/kg until harvested at day 42.
Histological analysis
Tissues were fixed for 48 hours in 10% neutral-buffered formalin (Sigma), and for knee joints, decalcified in TBD-2 (ThermoShandon) for 10 days. Four-micron sections of paraffinembedded tissue were processed for hematoxylin/eosin and Masson's trichrome staining or immunodetection of fibrin using a rabbit anti-mouse fibrin(ogen) polyclonal serum. 21 Images were captured using an Axioplan 2 microscope with Axiovision Image analysis software (Carl Zeiss Microimaging Inc). A semi-quantitative histopathology analysis was performed for each knee joint based on the following scoring criteria for CIA: inflammation (0-3), synovial hyperplasia (0-3), edema (0-3), pannus (0-1), and bone/cartilage loss (0-3) for a total histopathology index (0-26) for knees of a given animal.
Statistical analysis
The distribution of embryonic and neonatal genotypes was analyzed by Chi-squared analysis. Mouse survival data was analyzed using the Kaplan-Meier log-rank test. Differences in bleeding times, vessel occlusion times, thrombin generation, plasma APC levels, and arthritis parameters were analyzed using the Mann-Whitney U test or the paired t-test, as indicated.
Results
Mice carrying the prothrombin W215A/E217A allele To determine the physiological and pathological consequences of constitutive expression of thrombin zymogen with a specificity favoring protein C over procoagulant substrates, we generated founder mice carrying substitutions within the prothrombin gene that simultaneously resulted in: (i) the conversion of tryptophan 215 and glutamic acid 217 (residues numbered according to the chymotrypsin numbering system) to alanines, and (ii) the introduction of a novel
PvuII restriction enzyme site to assist in genotyping (see Figure 1A , 1B, and 1C 
Homozygosity for fII WE is compatible with development to term, but results in perinatal lethality
The phenotypic consequence of homozygous prothrombin W215A/E217A expression was first examined by intercrossing heterozygous mice to evaluate development and postnatal life. The number of fII WE/WE offspring noted on postnatal day 1 was significantly less than expected (see Table 1 ). Among 141 post-partum animals, the anticipated 1:2 ratio of fII heart, lungs, liver, gut, and pancreas (see Figure 2 panels G-V for representative comparative sections) as well as the thymus, spleen, and kidneys (data not shown).
Heterozygous fII WE mice exhibit a prolongation in bleeding time
The fact that fII WT/WE mice routinely survived to adulthood permitted a more comprehensive evaluation of the physiological and pathological consequences, if any, of the constitutive expression of 50% wild-type prothrombin and 50% prothrombin WE . Analyses of complete blood counts in control and fII WT/WE mice established that all blood cell parameters and differentials were comparable, including platelet counts (Table 3 and showing that the infusion of exogenous human thrombin WE resulted in extended plasma prothrombin times (PT) and activated partial thromboplastin times (aPTT) 13, 14 , no significant differences were observed between control and fII WT/WE mice in either the mean PT (10.4 ± 0.1 vs. 11.2 ± 0.1 seconds, respectively) or the mean aPTT (26.3 ± 0.6 vs. 24.9 ± 1.9 seconds, respectively To determine if a general shift in hemostatic function could be appreciated in vivo in fII WT/WE mice, tail-bleeding time analyses were performed. As shown in Table 3 , fII WT/WE mice displayed a significant prolongation in bleeding times relative to wild-type animals. The cessation of bleeding was achieved in 119 ± 12 seconds in wild-type mice, whereas 164 ± 8 seconds was required to control blood loss in fII WT/WE mice, a 40% increase in bleeding time (P<0.02). The prolongation in tail bleeding time was not simply a function of the fII WT/WE mice carrying half normal wild-type prothrombin as fII WT/Null mice displayed tail bleeding times of 119 ± 7 seconds, which is virtually identical to that observed for wild-type animals ( Table 3) . As a more direct analysis of the formation of thrombi in fII WT/WE and control mice, vessel occlusion was compared by real-time intravital microscopy within ~100 μm diameter mesenteric arterioles following FeCl 3 injury (Figure 4 ). No differences were observed in the time to initial thrombus formation following injury ( Figure 4A) ; however, consistent with the appreciably extended bleeding times observed in fII WT/WE mice, the time to complete vessel occlusion within injured mesenteric arterioles was significantly prolonged in fII WT/WE mice relative to wild-type control animals (an average of 15.0 ± 1.2 minutes compared to 10.6 ± 0.6 minutes (P <0.01),
respectively; see Figure 3B ). The longer average occlusion time observed in fII WT/WE mice was not a function of any genotype-dependent differences in animal weight, vessel diameter, or vessel shear rate, as these parameters were all comparable between genotypes ( Figure 4D ). Experimental parameters of animal weight, vessel diameter and shear rates were also similar between fII WT/Null mice and control animals ( Figure 5A ).
Furthermore, even at lower doses of LPS (i.e., ranging from the LD 50 over a two week period to a LD 100 ), no survival advantage was appreciable in fII WT/WE mice relative to control animals (data not shown). Complementary studies were done to directly compare plasma APC levels in control and mutant mice following LPS challenge using an established assay for murine APC (see Methods for details). Unchallenged wild-type and fII WT/WE mice exhibited similar levels of plasma APC at baseline (2.8 ng/ml vs. 3.5 ng/ml) and, as expected, plasma APC levels rose dramatically in mice of each genotype within hours following LPS challenge ( Figure 5B ).
However, circulating APC levels were modestly, but significantly, lower in fII WT/WE animals relative to wild-type mice at both 2 hours (11.8 vs. 6.6 ng/ml; P < 0.003) and 10 hours (13.2 vs.
9.3 ng/ml; P < 0.02) after LPS challenge. Although contrary to our initial expectations, the distinctly lower APC levels observed in fII WT/WE mice is compatible with overall diminished wild-type thrombin generation (i.e., mutant and wild-type thrombin competing for TM binding sites and the known modest reduction in fII WE catalytic efficiency with protein C). Consistent with this notion, TAT complexes were higher in the plasma of LPS challenged wild-type mice compared to challenged fII WT/WE mice ( Figure 5C ). Whether rates of local APC generation are elevated in fII WE mice in other contexts, particularly in the context of a local, rather than systemic challenge, is an unresolved question that will require additional study.
For Figure 6A ). Genotype-dependent differences were appreciable just days after the secondary CII immunization on d21 and persisted to the end of the evaluation period.
This analysis was performed three times with similar results. Similar to studies of bleeding time and vessel occlusion, differences in CIA observed in fII WT/WE mice do not appear to be merely a function of half-normal levels of wild-type prothrombin since CIA severity was found to be generally similar in DBA/1 fII WT/Null and wild-type mice (data not shown).
At day 42 of the CIA protocol, knee joints from both fII WT/WE and wild-type mice were harvested for microscopic analysis. Midline sagittal sections of knee joints were graded by investigators blinded to animal genotype for histological features of inflammatory joint disease including inflammatory cell infiltrate, synovial hyperplasia, edema, pannus formation, and
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Individual parameter scores were summed for each mouse to establish a total histopathology score. As expected, unchallenged control and fII WE mice were indistinguishable with regard to overall joint architecture and microscopic appearance (data not shown). However, the knee joints from CIA-challenged fII WT/WE mice exhibited significantly less evidence of joint pathology than wild-type mice with regard to each of the microscopic parameters evaluated ( Figure 6B ).
Furthermore, the total histopathology score affirmed a significant diminution in joint disease in mice expressing fII WE relative to wild-type animals challenged in parallel. Representative sections of knee joints from control and mutant mice ( Figure 6C ) highlight the substantial qualitative benefit of the presence of fII WE in limiting local inflammatory joint disease. The knee joints of CIA-challenged wild-type animals were typically characterized by significant articular cartilage erosion with frequent obliteration of articular surfaces, invading granulation tissue and even loss of bone ( Figure 6C ), whereas the articular surfaces in challenged fII WE mice were often smooth, with largely unperturbed cartilage and intact bone. Finally, qualitatively less local fibrin deposition was apparent within knee joint tissues of CIA-challenged fII WE mice relative to challenged wild-type animals (see Figure 6C for representative images). Notably, the diminution in arthritis severity observed in fII WT/WE mice was not due to a reduced adaptive immune response to the CII/CFA immunization. Cultured T cells isolated from draining lymph nodes from mice of each genotype responded similarly when challenged with CII antigen or when directly stimulated with a T cell receptor antibody ( Figure 6D ). Similarly, anti-CII antibody titers of total IgG and the IgG 1 and IgG 2A subclasses were found to be similar between wild-type and fII WT/WE mice ( Figure 6E ). Multiple independent studies have established that the constitutive elimination of prothrombin commonly results in mid-gestation developmental failure (e.g., 60-80% embryonic lethality at E9.5). 34, 35 However, the failure of prothrombin-deficient embryos does not appear to be related to hemostasis, but rather appears to be a deleterious consequence of lost thrombinmediated PAR-1 signaling. 36 The finding that homozygous fII WE/WE mice, unlike either fII-or 38, 39 In this regard, thrombin WE binding to GPIbα has been shown to antagonize platelet interactions with vWF under shear conditions, which could competitively limit both platelet engagement of vWF and platelet-associated prothrombotic activity. 38 In addition, thrombin WE may also contribute to overall phenotype by competitively acting to limit wild-type thrombin interactions with a variety of downstream substrates including factors XI, VIII, V, XIII, and
PARs. Even the zymogen form of prothrombin WE may also contribute to overall phenotype in fII WT/WE mice. Here, the dominant-negative competition between wild-type prothrombin and prothrombin WE for activation by prothrombinase complexes would be expected to limit the rate of wild-type thrombin generation at sites of injury, leading to both a proximal reduction in platelet activation and fibrin conversion and as well as a distal reduction in TM-regulated APC generation. Plasma-based thrombin generation assays suggest that the fII WE zymogen can competitively limit wild-type prothrombin activation by prothrombinase under some conditions. This, together with the modest reduction in catalytic efficiency of thrombin WE for protein C, is likely to account for modest, but initially unanticipated, lower levels of plasma APC observed in fII WT/WE mice following LPS challenge. The impact of fII WE is likely multifaceted and the premiere effect mechanisms may differ based on the underlying challenge (e.g., vascular injury, infection, immunological challenge), location, and time.
Consistent with the hypothesis that thrombin-mediated proteolysis can mediate inflammatory processes, these studies revealed that at least one striking benefit of circulating prothrombin WE is the amelioration of inflammatory joint disease. Because thrombin engages multiple substrates and receptors that participate in the control of inflammation, this approach may offer some advantages over interventions at the level of individual thrombin targets. Fibrin deposition within the joint space is a conspicuous and consistent feature of both human rheumatoid arthritis and murine CIA. 16, 18, 21, 40 We recently demonstrated that the genetic elimination of fibrin(ogen) dramatically reduced CIA disease severity. 21 The finding here that fibrin deposition is qualitatively reduced within the joints of CIA-challenged fII WT/WE mice points to one simple mechanism that would account for the reduced disease severity. However, other mechanisms may contribute to the outcome in CIA-challenged fII WT/WE mice. First, thrombin WE is known to be an inefficient activator of PARs and both PAR-1 and PAR-4 were reported to contribute to the severity of inflammatory joint disease. 22, 41 Second, thrombin WEmediated antagonism of GPIbα interactions with vWF and/or wild-type thrombin may limit the pro-arthritic activity of platelets. 38 Platelets and platelet-derived microparticles were recently shown to be potent drivers of CIA based on platelet depletion and platelet receptor modification studies 42 Finally, thrombin WE could potentially limit the progression of inflammatory joint disease via local generation of the anti-coagulant APC, an enzyme also known to have potent anti-inflammatory, cytoprotective, anti-apoptotic and barrier stabilization activities. Exogenous thrombin WE administration was reported previously to result in advantageous endogenous APC generation. 43 Based on the well documented beneficial in vivo effects of APC in sepsis, 23 ischemic stroke, [44] [45] [46] [47] ALS, 48 lung inflammation, 49 and neuroinflammatory disease, 50 and the documented role of thrombin and thrombin targets in inflammatory joint disease, [19] [20] [21] [22] APC and APC derivatives with anti-inflammatory/barrier protective properties are likely to limit arthritic disease. Whatever the precise benefits of fII WE in CIA, they are not tied to the capacity of the mutant mice to develop an autoimmune response, but rather are coupled to changes in proteolysis within the joint space to alter subsequent disease progression. Consistent with this view, a significant extension of the genetic analyses was the demonstration that intravenous administration of active murine thrombin WE to CIA-challenged mice also significantly dampened the development of inflammatory joint disease. Taken together, these results provide a proof-ofprinciple that pharmacological interventions imposing pro/thrombin specificity variants, or small-molecule agents that impose alterations in thrombin specificity, may offer therapeutic opportunities for the treatment of inflammatory diseases. 
